Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
06 Dec 2022 04:40 PM
RNS
Second Price Monitoring Extn
06 Dec 2022 04:35 PM
RNS
Price Monitoring Extension
21 Nov 2022 03:18 PM
RNS
Result of Annual General Meeting
07 Nov 2022 07:00 AM
RNS
Licenses Vaccitech technology to advance Modi-2
31 Oct 2022 07:00 AM
RNS
First patient dosed in expansion phase of ModiFY
28 Oct 2022 03:00 PM
RNS
Notice of AGM
28 Oct 2022 07:00 AM
RNS
Results for the year ended 30 April 2022
26 Oct 2022 07:00 AM
RNS
Directorate Changes
25 Oct 2022 04:42 PM
RNS
Second Price Monitoring Extn
25 Oct 2022 04:37 PM
RNS
Price Monitoring Extension
25 Oct 2022 02:05 PM
RNS
Second Price Monitoring Extn
25 Oct 2022 02:00 PM
RNS
Price Monitoring Extension
25 Oct 2022 11:05 AM
RNS
Second Price Monitoring Extn
25 Oct 2022 11:00 AM
RNS
Price Monitoring Extension
25 Oct 2022 07:00 AM
RNS
Signs Commercial License Agreement with Genmab
13 Oct 2022 07:00 AM
RNS
Change of Nominated Adviser
28 Sep 2022 12:31 PM
RNS
Holding(s) in Company
23 Sep 2022 07:00 AM
RNS
Preclinical data at the EuroMAbNet Annual Meeting
06 Sep 2022 12:54 PM
RNS
Change of Registered Office
16 Aug 2022 02:00 PM
RNS
First patient dosed in Cohort 2 of the ModiFY
23 Jun 2022 07:00 AM
RNS
Scancell to produce TCB antibodies
15 Jun 2022 02:06 PM
RNS
Second Price Monitoring Extn
15 Jun 2022 02:00 PM
RNS
Price Monitoring Extension
15 Jun 2022 07:00 AM
RNS
Phase 2 SCOPE trial of SCIB1 vaccine expanded
13 Jun 2022 07:00 AM
RNS
First patient dosed in Modi-1 Phase 1 trial
12 Apr 2022 03:47 PM
RNS
Change of Registered Holder of Shares
11 Apr 2022 02:06 PM
RNS
Second Price Monitoring Extn
11 Apr 2022 02:00 PM
RNS
Price Monitoring Extension
11 Apr 2022 11:05 AM
RNS
Second Price Monitoring Extn
11 Apr 2022 11:00 AM
RNS
Price Monitoring Extension
11 Apr 2022 07:00 AM
RNS
Modi-1 Phase 1/2 trial open for recruitment
29 Mar 2022 07:00 AM
RNS
Update on COVIDITY clinical trial
17 Mar 2022 07:00 AM
RNS
Scancell progresses its new anti-glycan mAb
03 Mar 2022 09:55 AM
RNS
Director Dealing
31 Jan 2022 07:00 AM
RNS
Update on COVIDITY Phase 1 clinical trial
26 Jan 2022 07:00 AM
RNS
Interim Results for the 6 months ended 31 Oct 2021
22 Dec 2021 09:45 AM
RNS
Notice of Interim Results
13 Dec 2021 04:41 PM
RNS
Second Price Monitoring Extn
13 Dec 2021 04:36 PM
RNS
Price Monitoring Extension
23 Nov 2021 03:58 PM
RNS
Result of AGM
19 Nov 2021 07:00 AM
RNS
First patient dosed in SCIB1 Phase 2 trial
03 Nov 2021 10:28 AM
RNS
Director Dealing
02 Nov 2021 10:07 AM
RNS
Director Dealing
01 Nov 2021 09:50 AM
RNS
Notice of Annual General Meeting
29 Oct 2021 07:00 AM
RNS
Results for the year ended 30 April 2021
28 Oct 2021 11:23 AM
RNS
Extension of CLN Redemption Dates
19 Oct 2021 07:00 AM
RNS
New facilities at The Oxford Science Park
15 Oct 2021 07:00 AM
RNS
Notice of Final Results
05 Oct 2021 04:22 PM
RNS
First subject dosed in COVIDITY clinical trial
09 Sep 2021 04:31 PM
RNS
PDMR dealing

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings